Back to the Virtual Exhibit Hall
| ||||
REBLOZYL is a trademark of Celgene Corporation, a Bristol-Myers Squibb Company. REBLOZYL is licensed from Acceleron Pharma Inc. © 2021 Bristol-Myers Squibb Company. 2007-US-2200003 01/22
|
Contact Information Bruce Shepman Senior Specialist Pittsburgh, Cleveland, Columbus, Buffalo, Rochester, Morgantown 412-352-2527 |
Acceleron Pharma Inc., a wholly-owned subsidiary of Merck Sharp & Dohme Corp, is dedicated to the discovery, development, and commercialization of medicines. Together with our global collaboration partner, Bristol Myers Squibb, we are pioneering the development of Reblozyl.
Please see U.S. Full Prescribing Information for REBLOZYL® (luspatercept-aamt) REBLOZYL® (luspatercept-amt First Indication Brochure-Shortened REBLOZYL (luspatercept-aamt) Second Indication Brochure-Shortened REBLOZYL (luspatercept-aamt) Dual Indication Dosing and Reconstitution Guide
| ||
